BioCentury | Nov 23, 2019
Product Development

Sanofi adds in home-grown trispecific antibody technology to grow oncology franchise

Promising preclinical data from a trispecific mAb platform developed by Sanofi could provide a new growth platform for its cancer pipeline, as the pharma seeks to wean off its reliance on Regeneron. Sanofi (Euronext:SAN; NYSE:SNY)...
BC Innovations | Mar 13, 2019
Distillery Therapeutics

Cocktails of AAV vectors encoding anti-HIV bNAbs to treat the infection

DISEASE CATEGORY: Infectious disease INDICATION: HIV/AIDS Non-human primate studies suggest cocktails of viral vectors encoding broadly neutralizing antibodies (bNAbs) against multiple HIV antigens could help treat HIV. The antibodies consist of variable regions of previously...
BC Innovations | Oct 12, 2017
Translation in Brief

Reservoir targets

As priorities in HIV drug development are shifting from suppressing viral replication to clearing the virus completely, attention has turned toward eliminating the latent viral reservoir. Toward that end, a group of Italian researchers has...
BC Innovations | Aug 9, 2017
Distillery Techniques

Disease models

TECHNOLOGY: Animal models Cows could be used to generate bNAbs against HIV. In four cows, immunization with an HIV env mimic elicited antibodies in all animals, one of which produced antibodies that neutralized 23 (20%)...
BC Innovations | Nov 30, 2016
Translation in Brief

A shocking vaccine

After more than 15 years of failed “shock and kill” strategies in HIV patients on antiretroviral therapy (ART), designed to flush out the last traces of virus, a new take on the method has finally...
BC Week In Review | Aug 3, 2015
Clinical News

BioPlex 2200 HIV Ag-Ab regulatory update

FDA approved a PMA from Bio-Rad for its BioPlex 2200 HIV Ag-Ab assay, which detects HIV antigens and antibodies and differentiates between HIV-1 and HIV-2. The HIV Ag-Ab kit assay runs on Bio-Rad’s BioPlex 2200...
BC Innovations | Jul 23, 2015
Product R&D

Sealing the envelope

Research from two academic groups could bring HIV vaccines a step closer to the finish line by identifying new ways to stabilize trimers of the HIV envelope protein. The greater stability raises the chances that...
BC Week In Review | Jun 23, 2014
Company News

Bio-Rad Laboratories Inc sales and marketing update

Bio-Rad launched outside of the U.S. its BioPlex 2200 HIV Ag-Ab kit, which detects HIV antigens and antibodies and differentiates between HIV-1 and HIV-2. The kit runs on Bio-Rad’s BioPlex 2200 system - an immunoassay platform...
BC Innovations | May 1, 2014
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS Not applicable In vitro studies suggest inducing an IgG3 response against HIV antigens could help create protective immunity against infection. In a clinical...
BC Innovations | Nov 14, 2013
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS HIV gag polyprotein; HIV p27 (nef); HIV pol; HIV env Macaque studies suggest mosaic HIV antigens delivered with a prime and boost vaccination...
Items per page:
1 - 10 of 45